Hontecillas-Prieto, L., García-Domínguez, D., Palazón-Carrión, N., García-Sancho, A., Nogales-Fernández, E., Jiménez-Cortegana, C., . . . de la Cruz-merino, L. (2024). CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Citación estilo ChicagoHontecillas-Prieto, L., et al. CD8+NKs As a Potential Biomarker of Complete Response and Survival With Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. 2024.
Cita MLAHontecillas-Prieto, L., et al. CD8+NKs As a Potential Biomarker of Complete Response and Survival With Lenalidomide Plus R-GDP in the R2-GDP-GOTEL Trial in Recurrent/refractory Diffuse Large B Cell Lymphoma. 2024.